Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Clin Case Rep 2018 Feb;6(2):442-443
Date
02/16/2018Pubmed ID
29445495Pubmed Central ID
PMC5799646DOI
10.1002/ccr3.1371Abstract
Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.